Table 1 Characteristics of the study group.
Parameter | All patients | Patients diagnosed 2012–2016 | Patients diagnosed 2017–2021 | |
|---|---|---|---|---|
Demographic characteristics | ||||
Group size, n (%) | 109 (100) | 41 (37.6) | 68 (62.3) | |
Sex distribution: female/male n (%) | 54 (49.5)/55 (50.5) | 19 (46.3)/22 (53.7) | 35 (51.5)/33 (48.5) | |
Age at allo-HCT, y, median (range) | 49 (18–72) | 45 (20–65) | 51 (18–72) | |
Diagnosis, n (%) | ||||
AML | 51 (46.7) | 20 (48.7) | 31 (45.6) | |
ALL | 26 (23.9) | 9 (22.0) | 17 (25.0) | |
MPN/MDS | 20 (18.3) | 9 (22.0) | 11 (16.2) | |
MM/HL/NHL/CLL | 12 (11.0) | 3 (7.3) | 9 (13.2) | |
HCT-CI (n = 106), n (%) | ||||
0 | 45 (42.4) | 21 (51.2) | 24 (36.9) | |
1–2 | 34 (32.1) | 16 (39.0) | 18 (27.7) | |
3–5 | 27 (25.5) | 4 (9.8) | 23 (35.4) | |
Transplant characteristics | ||||
Donor type, n (%) | Matched sibling donor | 32 (29.4) | 16 (39.0) | 16 (23.5) |
Unrelated donor (matched; mismatched) | 65 (59.6) | 22 (53.7) | 43 (63.2) | |
Haploidentical | 12 (11.0) | 3 (7.3) | 9 (13.2) | |
Graft source: PB/BM, n (%) | 106 (97.2)/3 (2.8) | 40 (97.6)/1 (2.4) | 66 (97.0)/2 (3.0) | |
Conditioning regimen: MAC or RTC/RIC, n (%) | 72 (66)/37 (34) | 32 (78)/9 (22) | 40 (58.8)/28 (41.2) | |
Day of neutrophil engraftment ANC > 0.5 G/l (if achieved), median (range) | 17 (6–43) | 19 (10–43) | 17 (6–43) | |
Engraftment not achieved, n (%) | 4 (3.7) | 1 (2.4) | 3 (4.4) | |
